Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to take part in the clinical research voluntarily
- People aged between 18 and 75 years, of any sex
- People with a general health and activity level that meets the study's requirements — a score of 0–1 during the dose-finding stage, or 0–2 during the dose-expansion stage (confirm with trial site what these scores mean for your situation)
- People whose cancer has been confirmed by a tissue sample (biopsy) to be Hodgkin's lymphoma or Anaplastic large cell lymphoma, and whose cancer cells test positive for a protein called CD30
- People who have at least one measurable area of cancer that can be tracked during the trial
- People with an expected survival of at least 3 months
- People whose blood test and other lab results fall within the ranges required by the study
- People who are willing and able to use effective contraception during the trial
Who may not be able to join:
- People who have recently received other cancer treatments and have not waited long enough since their last treatment (confirm with trial site what the required waiting period is)
- People who have previously been treated with CAR-T cell therapy or a stem cell transplant from a donor
- People with serious underlying health conditions (confirm with trial site for specific details)
- People who test positive for Hepatitis B surface antigen, active Hepatitis B virus, active Hepatitis C virus, or HIV antibodies
- People with other significant existing medical conditions that, in the treating doctor's judgement, would make participation in the study inappropriate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 13524488296
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence, severity, and type of treatment-emergent adverse events (TEAEs); Pharmacokinetics in peripheral blood; Pharmacokinetics in peripheral blood; Pharmacokinetics in bone marrow; Pharmacokinetics in bone marrow; Recommended Phase 2 Dose (RP2D) regimen finding
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.